The Latest News on Biologics for Kids with RA in Australia

I do not support any particular drug company. However, the need for biologic medicines which are accessible quickly in Australia continues to be something which I will always be passionate about. The following is great news for children with RA in Australia.

This is from one of Australia’s leading paediatric rheumatologists, Dr Jeffrey Chaitow.

About the TGA approval and Dr Chaitow’s comment

  • Children in Australia living with systemic Juvenile Idiopathic Arthritis (sJIA), a rare and aggressive form of arthritis, now have access to an approved biologic treatment following the Therapeutics Goods Administration (TGA) approving Actemra® (tocilizumab) for the treatment of sJIA in patients two years of age and older. This approval for juvenile patients follows its current availability for adults with severe active Rheumatoid Arthritis (RA) on the Pharmaceutical Benefits Scheme (PBS).
  • Head of the Department of Rheumatology at The Children’s Hospital at Westmead, Sydney, Dr Jeffrey Chaitow, said the decision to approve Actemra® for children with this severe form of juvenile arthritis is very welcome.
  • Dr Chaitow said: “sJIA is a debilitating disease characterised by persistent fevers, swollen and painful joints which significantly impact on a child’s quality of life.  Many have difficulty walking and rely on their parents and carers for help with simple daily tasks. They may experience isolation and loss of self-esteem as their ability to play with friends, attend school and participate in sport is also impacted.”